semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson's Disease Patients who meet the Parkinson's disease of United Kingdom Brain Bank within the study centres  Patients with vascular Parkinsonism (history of stroke) Patients with treatment induced Parkinsonism Patients with history of dopaminergic neurotoxin (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Parkinson Disease Patients with clinical diagnosis of idiopathic Parkinson's disease Male and female Stage 1-3 of the Hoehn and Yahr scale  Have other neurological diseases They have decompensated systemic diseases Musculoskeletal changes that prevent the achievement of movements With lowering of the cognitive level assessed using the MiniMental State examination with cutoff point according to education With respiratory impairment With medical restrictions for performing exercises In physical therapy, occupational therapy service for 3 months or more;
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Patients affected by mild to moderate PD, according to motor examination section (Part III) of the Unified Parkinson's Disease Rating Scale (UPDRS III) ability to independently perform motor rehabilitation absence of cognitive impairment (MMSE >25)  severe hearing loss and/or visual deficit serious comorbidity making impossible to perform rehabilitation (postural hypotension, heart disease, stroke, severe shoulder-hip disease)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Huntington Disease Agreeing to participate in the study French mother tongue MMSE > 20/30 Specific to the MP and MH Parkinson's disease defined by the of the stage 1 , 2 or 3 Hoehn and Yahr (ON) age of onset of the disease known brain MRI performed during follow-up Huntington disease   Illiteracy, writing or reading difficulties Visual perceptual auditory deficit or preventing reading, drawing, writing or understanding instructions Visual hallucinations Significant history may sound on cognition (unbalanced thyroid dysfunction, ischemic heart disease or embolic unstabilized or symptomatic, progressive neoplasia, chronic alcoholism weaned or not) Current or previous neurological diseases other than MH or MP: ischemic cerebral vascular accident or bleeding, head injuries (loss of higher knowledge in 15 minutes), epilepsy requiring treatment Psychiatric disorders depression unless treated (stable treatment for 1 month) Psychotropic treatment (except anxiolytic, antidepressant steady since 1 month) Inability to achieve an autonomous operation without technical assistance over a distance of 20 meters Inability to stand without technical assistance for 30 seconds
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Parkinson's Disease for  Parkinson's Disease (UK Parkinson's Disease Society Brain Bank Criteria) No Deep Brain Stimulation (DBS) From 40 to 80 years old. for  From 40 to 80 years old  for  Dementia (MoCA < 24) Atypical parkinsonism (MSA, PSP, …) Severe current psychiatric or somatic disease Iron treatments (Desferal® (deferoxamine), Ferriprox® (deferiprone) et Exjade® (deferasirox), Fumafer® (ferrous fumarate), Tardyferon® (ferrous sulfate (II)),…), Ferinject® (ferric carboxymaltose), Venofer® (iron sucrose),…) Contra-indication to MRI (claustrophobia, pace maker,…) for  Neurological disease Psychiatric or somatic disease Dementia (MoCA < 24)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Castleman Disease Castleman's Disease Giant Lymph Node Hyperplasia Angiofollicular Lymph Hyperplasia Angiofollicular Lymph Node Hyperplasia Angiofollicular Lymphoid Hyperplasia GLNH Hyperplasia, Giant Lymph Node Lymph Node Hyperplasia, Giant Person of any age Have a reference pathology report suggesting "Castleman disease" not limited to cutaneous involvement only that can be uploaded Be able to provide electronic informed consent, as per local regulations Deceased patients may also be enrolled when a reference pathology report suggesting "Castleman disease" can be supplied or when the ART is able to locate and upload such a pathology report  Because this registry is designed to provide as wide a picture of routine clinical practice as possible, are set deliberately wide and there are no
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Parkinson's Disease Stage 1 Male or female subjects between 45 and 78 years of age inclusive Willing and able to give informed consent Idiopathic PD, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Rest tremor amplitude score of ≥2 in any limb on question 3.17 of the MDS-UPDRS (ON state) Anti-parkinsonian medication is fixed for at least 1 month prior to study entry If MoCA<22 subject must have a legally authorized representative (LAR) sign the consent, and must have a designated caregiver that agrees to ensure study protocols followed. This includes accompanying patient to study visits and being available for study phone calls Must have a driver to drive them to and from study visits Has a significant other (someone who knows the subject well) that is appropriate for doing the NPI assessment, can accompany patient to study visits, and agrees to do so Agrees to not take more than 1 gram per day of acetaminophen, due to a possible interaction with study drug that could increase risk of hepatotoxicity  Known or suspected allergy to cannabinoids or excipients used in the study drug formulation Cannabinoids taken currently or in the previous 30 days History of drug or alcohol dependence; defined by prior inpatient stay(s) for this or that patient stats s/he has a history of this Use of dopamine blockers within 180 days and amphetamine, cocaine, and MAO-A inhibitors within 90 days of baseline Currently taking tolcapone, valproic acid, felbamate, niacin, isoniazid and ketoconazole due to risk of liver injury and clobazam and ketoconazole because of risk of toxic interactions with the study drug. These medications need to be stopped 90 days before the baseline visit Unstable medical condition Any of the following laboratory test results at screening
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Non-Small-Cell Lung Cancer ≥19 years of age 2. Patients with a primary diagnosis of NSCLC within the past 5 years who are eligible for their first systemic therapy based on disease characteristics. Systemic therapy may any cytotoxic, targeted, immune-based, or otherwise non-local treatment modality. Specific allowed settings the following: 1. Incident metastatic disease (stage IV) undergoing palliative therapy 2. Non-metastatic disease undergoing adjuvant, neoadjuvant, or concurrent chemoradiation with either curative or palliative intent 3. Recurrent or subsequently metastatic disease (any stage) 3. Pathologic confirmation of malignancy prior to initiation of first systemic therapy 4. Submission of archival biospecimen sample(s) (collected up to two years prior) for analysis 5. Availability of key variables at the time of screening (e.g. stage, demographics) 6. Have been fully informed and are able to provide written consent for longitudinal follow-up and agree to be accessible by phone 7. Patients may be concurrently enrolled in unblinded clinical trials, but not blinded clinical trials in which the treatment being administered is unknown  Pre-specified enrollment caps have been met (Figure 1) 2. Suspected recurrent or subsequently metastatic disease that is not biopsy confirmed prior to receipt of initial systemic therapy
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dermatological Emergency Male or female aged ≥ 18 years Written informed consent prior to study participation Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel Dermatological emergency patient  Male or female aged < 18 years Missing informed consent prior to study participation Patient has been committed to an institution by legal or regulatory order Persons in dependence from the sponsor or working with the sponsor Participation in another clinical trial within the previous 2 months
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Parkinson's Disease Patients 19 and older Referred for clinical DaTscan for possible PD Controls from the PPMI dataset  Pregnant women Participants that cannot participate in MRI (metallic artifact or other contraindication(s) to MRI at 3T)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Man or woman ≥ 18 years old Caucasian origin Parkinson's disease considered to be probable as defined by the of UK Parkinson's disease Brain Bank (Hugues and coll 2002) Absence of anti-parkinsonian medication Patient affilied to a social security system Signed information consent form  Parkinsonian syndrome secondary to neuroleptics Atypical parkinsonian syndrome such a multisystem atrophy, progressive supranuclear paralysis, dementia with levy bodies MRI contraindication (claustrophobia, not compatible mechanical heart valve MRI, pacemaker, cochlear implant, other body ferromagnetic objects, pregnancy) MPET contraindication (pregnancy, feeding, hypersensitivity to ioflupane [123] Patient under guardianship or trusteeship Any other significant pathology that could prevent patient participation and achievement of planned examinations (except for lumbar puncture) Patient participating or having participated in other biomedical research involving a drug in the three months prior to Specific if lumbar puncture is accepted by the patient: Anticoagulation or antiplatelet treatment; history of hemostasis disorders; platelets <150,000 mm3; TP <80%; TCA (patient / control)> 1.2 Hypersensitivity to local anesthetics with amide link or to any of the excipients
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Parkinson's Disease A. Parkinson's Disease patients 1. Diagnosis of Parkinson's disease, based on UK Brain Bank and made within the preceding 3 years ('recent onset cases') or diagnosed at under 50 years ('under 50 years cases') 2. Age ≥18 to <90years 3. Subject is able and willing to provided informed consent  Patient has severe comorbid illness that would prevent full study participation 2. Patient has features indicating another type of degenerative parkinsonism, e.g. progressive supranuclear palsy 3. Drug-induced parkinsonism (Drug-unmasked PD is allowed) 4. Symmetrical lower body parkinsonism attributable to significant cortical and/or subcortical cerebrovascular disease (patients with 'incidental' small vessel disease on brain imaging are allowed). 5. Negative or normal functional imaging of the presynaptic dopamine system 6. The presence of UK Brain Bank will be recorded at baseline, allowing for the presence of 1 or 2 (e.g. dopamine antagonist Drug used; more than one affected relative) (if justified e.g. by abnormal SPECT). B. First degree relatives 1. Age ≥18 to < 90years 2. Resident in the United Kingdom and able to access one of the PRoBaND study centres. 3. Subject is able and willing to provided informed consent Subject has severe comorbid illness that would prevent study participation 2. Subject already has a diagnosis of Parkinson's disease
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Parkinson's Disease Essential Tremor Patient foreseen to undergo DBS for Parkinson's disease or Essential Tremor according to routine of the center. For Parkinson Disease Person is between 18 and 75 years of age Established diagnosis of idiopathic Parkinson's disease with progression of symptoms for a minimum of 2 years Person has a history of at least 30% improvement on the UPDRS therapy in L-dopa (levodopa), except in the case of tremor dominant patient Weak control of symptoms by dopaminergic therapy (off phenomenon, fluctuations on / off, dyskinesia on) For Essential Tremor Person is between 18 and 80 years of age Established diagnosis of Essential Tremor for a minimum of 2 years Functional disability due to tremor was not adequately controlled by medication for at least 3 months prior to implant. Person has given his/her written consent  Person suffering from an active major psychiatric disorder Mattis Dementia Rating Scale score <130 or otherwise not capable of discernment Presence of major co-morbidity or medical condition that may affect participation to the study Presence of an electrical or electromagnetic implant (e.g., cochlear implant, pacemaker) Person with a previous surgery for the treatment of Parkinson's disease or Essential Tremor Person with a previous brain ablation procedure Person who suffers from epilepsy Person who is pregnant: a pregnancy test will be performed in patients of childbearing age Person with coagulopathies Abuse of drugs or alcohol
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Parkinson's Disease Persons who have been diagnosed with Parkinson disease age 45 years and older are eligible to participate in this study Healthy older individuals (ages 60-80) without neurologic problems are eligible to participate  Individuals using some drugs cannot participate. These anti-depressant medications, buproprion, or St. John's Wort, as well as dopamine antagonist medications Women of childbearing age may not participate Individuals unable to have MRI scans because of a pacemaker or metal fragments may not participate Individuals with a history of stroke may not participate. People with any contraindication of PET imaging such as previous participation in research procedures involving ionizing radiation may not be eligible to participate in this study